Assessment of Breast Cancer Risk with High Spectral and Spatial Resolution MRI

使用高光谱和空间分辨率 MRI 评估乳腺癌风险

• 批准号: 8792350
• 负责人: Gregory S. Karczmar
• 金额: $ 48.9万
• 依托单位: UNIVERSITY OF CHICAGO
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-02-08 至 2016-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8792350
• 关键词: 3-Dimensional; Affect; Age; Bilateral; Breast; Breast Cancer Risk Factor; Classification; Clinical; Computer Assisted; Computer software; Computer-Assisted Diagnosis; Development; Evaluation; Fatty acid glycerol esters; Goals; Image; Individual; Laboratories; Magnetic Resonance Imaging; Mammographic Density; Mammography; Measurement; Measures; Methods; Morphology; Patients; Performance; Pharmaceutical Preparations; Physiologic pulse; Preventive; Protons; Raloxifene; Research; Resolution; Risk; Risk Management; Risk Marker; Roentgen Rays; Selective Estrogen Receptor Modulators; Signal Transduction; Tamoxifen; Testing; Texture; Therapeutic Agents; Three-Dimensional Imaging; Validation; Variant; Visual; Water; Woman; Work; base; breast density; cancer risk; density; effective therapy; imaging modality; improved; innovation; malignant breast neoplasm; novel; novel marker; novel therapeutics; population based; public health relevance; response; saturated fat; spectroscopic imaging; tool; treatment planning

DESCRIPTION (provided by applicant): We propose to test whether HiSS MRI estimates breast cancer risk more accurately than conventional fat- suppressed MRI and X-ray mammography. Reliable measurements of breast density, which is one of the strongest independent risk factors for breast cancer, could significantly improve management of risk and preventive treatment. X-ray mammography predicts increased cancer risk on a population basis but has limited value for guiding treatment of individual patients, due to errors in separation of parenchyma and fat, and errors in measurement of the parenchymal volume. MRI allows 3D imaging of breast parenchyma and detects independent signals from water and fat. MRI detects significant decreases in breast density due to tamoxifen and raloxifen. However, conventional MRI requires suppression of signals from fat in the breast. Fat suppression is sometimes non-uniform and fat suppression pulses affect the water resonance, reducing the accuracy of parenchymal volume measurements. Therefore we propose an innovative approach to measurement of breast cancer risk: We will use high spectral and spatial resolution MR imaging (HiSS MRI) to reliably separate water and fat signals, and to quantitatively measure parenchymal density and changes in breast density due to tamoxifen. We hypothesize that use of quantitative HiSS imaging will reduce variability, standardize measurements, and increase sensitivity to variations in parenchymal volume. In addition, HiSS may provide new markers for risk based on the novel computer-aided diagnosis (CAD) analysis of the enhanced texture of HiSS images, and HiSS images of fat distribution. This proposal builds on work in this laboratory that implemented HiSS MRI on clinical magnets and demonstrated significant advantages of this approach. We propose the following Specific Aims: Aim #1: Implement quantitative full bilateral measurements of breast parenchymal density and morphology with HiSS MRI. Phantoms attached to the breast will be used to accurately measure MRI- detectable proton density. Novel software will evaluate parenchymal volume and texture. Fat distribution and composition will be tested as additional markers for risk. Aim #2. Compare HiSS with conventional approaches: We will compare breast density measured with HiSS, conventional fat-suppressed MRI, Dixon MRI methods, and X-ray mammography. Measures of breast density will include absolute and fractional parenchymal volume, and MRI-detectable water proton density. The variability of HiSS and conventional MRI measurements will be compared. Aim #3. Measure changes in parenchymal density due to selective estrogen receptor modulator (SERM) therapy: As a measure of the sensitivity of HiSS MRI to changes in breast cancer risk, we propose to image response to preventive therapy that is known to reduce risk. We will compare the sensitivity of HiSS MRI to effects of tamoxifen therapy with that of 2D X-ray mammography and conventional MRI.

描述（由申请人提供）：我们建议测试 HiSS MRI 是否比传统的脂肪抑制 MRI 和 X 射线乳房X线照相术更准确地估计乳腺癌风险。乳腺密度是乳腺癌最强的独立危险因素之一，可靠的测量可以显着改善风险管理和预防性治疗。 X 射线乳房X 射线照相术可预测人群癌症风险增加，但由于实质和脂肪分离的误差以及实质体积测量的误差，对于指导个体患者的治疗价值有限。 MRI 可对乳腺实质进行 3D 成像，并检测来自水和脂肪的独立信号。 MRI 检测到他莫昔芬和雷洛昔芬导致乳腺密度显着降低。然而，传统的 MRI 需要抑制乳房脂肪的信号。脂肪抑制有时不均匀，脂肪抑制脉冲会影响水共振，降低实质体积测量的准确性。因此，我们提出了一种测量乳腺癌风险的创新方法：我们将使用高光谱和空间分辨率磁共振成像（HiSS MRI）来可靠地分离水和脂肪信号，并定量测量实质密度和他莫昔芬引起的乳腺密度变化。我们假设使用定量 HiSS 成像将减少变异性、标准化测量并提高对实质体积变化的敏感性。此外，基于对 HiSS 图像增强纹理和脂肪分布 HiSS 图像的新型计算机辅助诊断 (CAD) 分析，HiSS 可以提供新的风险标记。该提案建立在该实验室在临床磁体上实施 HiSS MRI 的工作基础上，并展示了这种方法的显着优势。我们提出以下具体目标： 目标#1：使用 HiSS MRI 实施乳腺实质密度和形态的定量全双侧测量。附着在乳房上的模型将用于精确测量 MRI 可检测的质子密度。新颖的软件将评估实质体积和纹理。脂肪分布和成分将作为额外的风险标记进行测试。目标#2。将 HiSS 与传统方法进行比较：我们将比较使用 HiSS、传统脂肪抑制 MRI、Dixon MRI 方法和 X 射线乳房 X 线摄影测量的乳腺密度。乳腺密度的测量包括绝对实质体积和分数实质体积，以及 MRI 可检测的水质子密度。将比较 HiSS 和传统 MRI 测量的变异性。目标#3。测量选择性雌激素受体调节剂 (SERM) 治疗引起的实质密度变化：作为 HiSS MRI 对乳腺癌风险变化敏感性的衡量标准，我们建议对已知可降低风险的预防性治疗的反应进行成像。我们将比较 HiSS MRI 对他莫昔芬治疗效果的敏感性与 2D X 射线乳房 X 线摄影和传统 MRI 的敏感性。